LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Начало・Списък с акции・Editas Medicine Inc

Editas Medicine Inc

Затворен

СекторЗдравеопазване

3.44

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.24

Максимум

3.49

Ключови измерители
By Trading Economics
Приходи	-19M -25M
Продажби	-22M 2.8M
EPS	-0.26
Марж на печалбата	-882.444
Служители	87
EBITDA	-19M -25M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+78.43% upside

Дивиденти
By Dow Jones
Следващи печалби	10.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-40M 254M
Предишно отваряне	3.44
Предишно затваряне	3.44

Настроения в новините

By Acuity

21%

79%

38 / 344 Класиране в Healthcare

Editas Medicine Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

28.05.2026 г., 22:47 ч. UTC

Печалби

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28.05.2026 г., 20:45 ч. UTC

Печалби

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28.05.2026 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28.05.2026 г., 23:39 ч. UTC

Пазарно говорене

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28.05.2026 г., 23:31 ч. UTC

Пазарно говорене

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28.05.2026 г., 23:17 ч. UTC

Пазарно говорене

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28.05.2026 г., 23:02 ч. UTC

Пазарно говорене

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28.05.2026 г., 22:41 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

28.05.2026 г., 22:41 ч. UTC

Пазарно говорене

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28.05.2026 г., 22:37 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

M&A-Related Insurance Payments In North America Rise -- Market Talk

28.05.2026 г., 22:04 ч. UTC

Придобивния, сливания и поглъщания

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28.05.2026 г., 22:04 ч. UTC

Придобивния, сливания и поглъщания

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28.05.2026 г., 21:12 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28.05.2026 г., 21:00 ч. UTC

Печалби

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28.05.2026 г., 20:57 ч. UTC

Печалби

Dell Stock Soars on Blowout Earnings -- Barrons.com

28.05.2026 г., 20:55 ч. UTC

Печалби

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

28.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

28.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

28.05.2026 г., 20:48 ч. UTC

Горещи акции

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28.05.2026 г., 20:34 ч. UTC

Печалби

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28.05.2026 г., 20:31 ч. UTC

Печалби

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28.05.2026 г., 20:28 ч. UTC

Печалби

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28.05.2026 г., 20:26 ч. UTC

Печалби

Dell Stock Soars on Blowout Earnings -- Barrons.com

28.05.2026 г., 20:20 ч. UTC

Печалби

Costco 3Q Membership Fees $1.37B

28.05.2026 г., 20:20 ч. UTC

Печалби

Costco 3Q Net Sales $69.15B

28.05.2026 г., 20:19 ч. UTC

Печалби

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28.05.2026 г., 20:19 ч. UTC

Печалби

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28.05.2026 г., 20:17 ч. UTC

Печалби

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28.05.2026 г., 20:17 ч. UTC

Печалби

Costco 3Q Same-Store Sales Up 9.8% >COST

Сравнение с други в отрасъла

Ценова промяна

Editas Medicine Inc Прогноза

Ценова цел

By TipRanks

78.43% нагоре

12-месечна прогноза

Среден 6.37 USD 78.43%

Висок 15 USD

Нисък 4 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Editas Medicine Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

11 ratings

Купи

Задържане

Продай

Според 11 анализатори, дали борсови рейтинги на Editas Medicine Inc през последните 3 месеца.

Настроение

By Acuity

38 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.